NCT02256696View on ClinicalTrials.gov

Assessing PA-824 for Tuberculosis (the APT Trial)

PHASE2CompletedINTERVENTIONAL
Enrollment

157

Participants

Timeline

Start Date

April 29, 2015

Primary Completion Date

May 1, 2022

Study Completion Date

May 1, 2022

Conditions
Pulmonary Tuberculosis
Interventions
DRUG

PA-824

200 mg QD

DRUG

Rifampin

600 mg QD

DRUG

Rifabutin

300 mg QD

DRUG

Pyrazinamide

25mg/kg QD

DRUG

Ethambutol

15mg/kg QD

DRUG

Isoniazid

300 mg QD

Trial Locations (1)

Unknown

University of Cape Town Lung Institute, Cape Town

All Listed Sponsors
collaborator

University of Cape Town

OTHER

lead

Johns Hopkins University

OTHER

NCT02256696 - Assessing PA-824 for Tuberculosis (the APT Trial) | Biotech Hunter | Biotech Hunter